Combination Chemotherapy in the Treatment of Follicular Low-Grade Lymphoma

References

• Horning S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lym-phomas. The New England Journal of Medicine 1984; 311: 1471–5
   PubMed Web of Science ®Google Scholar
• Bierman P., Vose J., Armitage J., Kessinger A. High-dose therapy followed by autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma (NHL). Proceedings of American Society of Clinical Oncology 1992; 11: 317, (abstract)
   Google Scholar
• Klasa R. J., Hoskins P. J., O'Reilly S. E., Fairey R., Voss N., Gascoyne R., Connors J. M. BP-VACOP and extensive lymph node irradiation (RT) for advanced stage low grade lymphoma. Proceedings of American Society of Clinical Oncology 1992; 11: 328, (abstract)
   Google Scholar
• Kennedy B. J., Bloomfield C. D., Kiang D. T., Vosika G., Peterson B. A., Theologides A. Combination versus successive single agent chemotherapy in lym-phocytic lymphoma. Cancer 1978; 41: 23–8
   PubMed Web of Science ®Google Scholar
• Jones S. E., Rosenberg S. A., Kaplan H. S., Kadin M. E., Dorfman R. F. Non-Hodgkin's lympho-mas:II. Single agent chemotherapy. Cancer 1972; 30: 31–8
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A., Glatstein E., Kaplan H. S. Treatment of advanced non-Hodg-kin's lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 1976; 47: 747–56
   PubMed Web of Science ®Google Scholar
• Lister T. A., Cullen M. H., Beard M. E.J., Brearley R. L., Whitehouse J. M.A., Wrigley P. F.M., Stansfeld A. G., Sutcliffe S. B.J., Malpas J. S., Crowther D. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favorable histological type. British Medical Journal 1978; 1: 533–7
   PubMed Web of Science ®Google Scholar
• Hoppe R. T., Kushlan P., Kaplan H. S., Rosenberg S. A., Brown B. W. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592–8
   PubMed Web of Science ®Google Scholar
• Hoogstraten B., Owens A. H., Lenhard R. E., Glidewell O. J., Leone L. A., Olson K. B., Harley J. B., Townsend S. R., Miller S. P., Spurr C. L. Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. Blood 1969; 33: 370–8
   PubMed Web of Science ®Google Scholar
• Luce J. K., Gamble J. F., Wilson H. E., Monto R. W., Isaacs B. L., Palmer R. L., Coltman C. A., Jr., Hewlett J. S., Gehan E. A., Frei E., III. Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma. Cancer 1971; 28: 306–17
   PubMed Web of Science ®Google Scholar
• Bagley C. M., Jr., De Vita V. T., Jr., Berard C. W., Canellos G. P. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Annals of Internal Medicine 1972; 76: 227–34
   PubMed Web of Science ®Google Scholar
• Portlock C. S., Rosenberg S. A. Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience. Cancer Treatment Reports 1978; 61: 1049–55
   Google Scholar
• Schein P. S., Chabner B. A., Cannellos G. P., Young R. C., Berard C., DeVita V. T. Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood 1974; 43: 181–9
   PubMed Web of Science ®Google Scholar
• Bruno S., Corrado C., Santarelli M. T., Garay G., So-moza N., Pinto Tezanos M., Pavlovsky S. Randomized trial of cyclophosphamide (C) versus cyclophosphamide, vincristine and prednisone (CVP) in low-grade lymphoma (LG-NHL). Proceedings of American Society of Clinical Oncology 1988; 7: 243, (abstract)
   Google Scholar
• Steward W. P., Crowther D., McWilliam L. J., Jones J. M., Deakin D. P., Todd D. H.I., Blackedge G., Wagstaff J., Scarffe J. H., Harris M. Maintenance chlor-ambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphomas. Cancer 1988; 61: 441–7
   PubMed Web of Science ®Google Scholar
• Ezdinli E., Pocock S., Berard C. W., Aungst C. W., Silverstein M., Horton J., Bennett J., Bakemeier R., Stolback L., Perlia C., Brunk F., Lenhard R. E., Klaas-sen D. J., Richter P., Carbone P. Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas. Cancer 1976; 38: 1060–8
   PubMed Web of Science ®Google Scholar
• Ezdinli E., Costello W., Silverstein M. Chemotherapy of prognostically favorable non-Hodgkin's lymphomas. Proceedings of American Society of Clinical Oncology 1978; 19: 310, (abstract)
   Google Scholar
• Ezdinli E. Z., Anderson J. R., Melvin F., Glick J. H., Davis T. E., O'Connell M. J. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. Journal of Clinical Oncology 1985; 3: 769–75
   PubMed Web of Science ®Google Scholar
• Ezdinli E. Z., Harrington D. P., Kucuk O., Silverstein M. W., Anderson J., O'Connell M. J. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 1987; 60: 156–60
   PubMed Web of Science ®Google Scholar
• Longo D. L., Young R. C., Hubbard S. M., Wesley M., Fisher R. I., Jaffe E., Berard C., DeVita V. T., Jr. Prolonged initial remission in patients with nodular mixed lymphoma. Annals of Internal Medicine 1984; 100: 651–6
   PubMed Web of Science ®Google Scholar
• Glick J. H., Barnes J. M., Ezdinli E. Z., Berard C. W., Orlow E. L., Bennett J. M. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920–5
   PubMed Web of Science ®Google Scholar
• Jones S. E., Grozea P. N., Metz E. N., Haut A., Stephens R. L., Morrison F. S., Butler J. J., Byrne G. E., Jr., Moon T. E., Fisher R., Haskins C. L., Coltman C. A., Jr. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 1979; 43: 417–25
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Frizzera G., Anderson J. R., Bloomfield C. D., Pajak T. F., Gottlieb A. J., Holland J. F. Response to low-grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisone and bleomycin (CAVPB). Proceedings of American Society of Clinical Oncology 1985; 4: 211, (abstract)
   Google Scholar
• Peterson B. A., Anderson J. R., Frizzera G., Bloomfield C. D., Gottlieb A. J., Holland J. F. Nodular mixed lymphoma (NML): A comparative trial of cyclophosphamide (CTX) and cyclophosphamide, adriamycin, vincristine, prednisone and bleomycin (CAVPB). Blood 1985; 66: 216, (abstract)
   Google Scholar
• Peterson B. A., Anderson J. R., Frizzera G., Bloomfield C. D., Propert K. J., Gottlieb A. J. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML). Proceedings of American Society of Clinical Oncology 1990; 9: 259, (abstract)
   Google Scholar
• Young R. C., Longo D. L., Glatstein E., Ihde D. C., Jaffe E. S., DeVita V. T., Jr. The treatment of indolent lymphomas: Watchful waiting v. aggressive combined modality treatment. Seminars in Hematology 1988; 25: 11–6
   PubMed Web of Science ®Google Scholar